EyePoint, Inc. (EYPT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 298.29M USD. 52-week range 3.05 to 19.11 USD. Data as of 2026-10-09.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with ...